Alterity Therapeutics Trading Halt for Capital Raise
Ticker: PRNAF · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: trading-halt, capital-raise, filing-update
TL;DR
ALTERITY halts trading for capital raise news - get ready.
AI Summary
Alterity Therapeutics Ltd. announced a trading halt on September 4, 2025, pending an announcement regarding a capital raising. The company, formerly known as Prana Biotechnology Ltd, is a development stage enterprise focused on pharmaceutical preparations.
Why It Matters
A trading halt indicates significant news is imminent, potentially impacting the stock price and investor decisions.
Risk Assessment
Risk Level: medium — Trading halts can precede significant positive or negative news, introducing uncertainty and volatility.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- Prana Biotechnology Ltd (company) — Former company name
- September 4, 2025 (date) — Date of trading halt
FAQ
What is the reason for the trading halt?
The trading halt was requested pending an announcement regarding a capital raising.
When was this Form 6-K filed?
This Form 6-K was filed on September 4, 2025.
What is Alterity Therapeutics Ltd.'s former name?
Alterity Therapeutics Ltd.'s former name was Prana Biotechnology Ltd.
What is the company's principal executive office address?
The company's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Which registration statements is this Form 6-K being incorporated by reference into?
This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Filing Stats: 186 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-09-04 06:24:19
Filing Documents
- ea0255973-6k_alterity.htm (6-K) — 14KB
- ea025597301ex99-1_alterity.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-1_002.jpg (GRAPHIC) — 9KB
- 0001213900-25-084256.txt ( ) — 44KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Trading Halt 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 4, 2025 2